Managing Cancer and Living Meaningfully (CALM): A Randomized Controlled Trial of a Psychological Intervention for Patients With Advanced Cancer

被引:165
|
作者
Rodin, Gary [1 ,2 ]
Lo, Christopher [1 ,2 ]
Rydall, Anne [1 ]
Shnall, Joanna [1 ]
Malfitano, Carmine [1 ]
Chiu, Aubrey [1 ]
Panday, Tania [1 ]
Watt, Sarah [1 ]
An, Ekaterina [1 ]
Nissim, Rinat [1 ,2 ]
Li, Madeline [1 ,2 ]
Zimmermann, Camilla [1 ,2 ]
Hales, Sarah [1 ,2 ]
机构
[1] Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
BRIEF INDIVIDUAL PSYCHOTHERAPY; EARLY PALLIATIVE CARE; DIGNITY THERAPY; DEPRESSION; DISTRESS; SCALE; ANXIETY; LUNG; END; DEATH;
D O I
10.1200/JCO.2017.77.1097
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeIndividuals with advanced cancer experience substantial distress in response to disease burden and impending mortality. Managing Cancer And Living Meaningfully (CALM) is a novel, brief, manualized psychotherapeutic intervention intended to treat and prevent depression and end-of-life distress in patients with advanced cancer. We conducted a randomized controlled trial to compare CALM with usual care (UC) in this population.MethodsPatients with advanced cancer were recruited from outpatient oncology clinics at a comprehensive cancer center into an unblinded randomized controlled trial. Permuted block randomization stratified by Patient Health Questionnaire-9 depression score allocated participants to CALM plus UC or to UC alone. Assessments of depressive symptoms (primary outcome), death-related distress, and other secondary outcomes were conducted at baseline, 3 months (primary end point), and 6 months (trial end point). Analyses were by intention to treat. Analysis of covariance was used to test for outcome differences between groups at follow-up, controlling for baseline. Mixed-model results are reported.ResultsParticipants (n = 305) were recruited between February 3, 2012, and March 4, 2016, and randomly assigned to CALM (n = 151) or UC (n = 154). CALM participants reported less-severe depressive symptoms than UC participants at 3 months ( = 1.09; P = .04; Cohen's d = 0.23; 95% CI, 0.04 to 2.13) and at 6 months ( = 1.29; P = .02; d = 0.29; 95% CI, 0.24 to 2.35). Significant findings for greater end-of-life preparation at 6 months also favored CALM versus UC. No adverse effects were identified.ConclusionFindings suggest that CALM is an effective intervention that provides a systematic approach to alleviating depressive symptoms in patients with advanced cancer and addresses the predictable challenges these patients face.
引用
收藏
页码:2422 / +
页数:17
相关论文
共 50 条
  • [41] In Regard to Ding et al. 2020: "Managing Cancer and Living Meaningfully (CALM) Intervention on Chemotherapy-Related Cognitive Impairment in Breast Cancer Survivors"
    Zarrella, Giuliana V.
    Braun, Sarah E.
    INTEGRATIVE CANCER THERAPIES, 2023, 22
  • [42] INCLUDING BRAIN METASTASES PATIENTS IN PSYCHOLOGICAL INTERVENTIONS: A PHASE II SINGLEARM INVESTIGATION OF MANAGING CANCER AND LIVING MEANINGFULLY
    Loughan, Ashlee
    Lanoye, Autumn
    Davies, Alexandria
    Willis, Kelcie
    Braun, Sarah
    Kleva, Chris
    Fox, Amber
    Zarrella, Giuliana
    Rodin, Gary
    NEURO-ONCOLOGY, 2023, 25
  • [43] Pilot randomized controlled trial of a symptom cluster intervention in advanced cancer
    Wells-Di Gregorio, Sharla M.
    Marks, Donald R.
    DeCola, Joseph
    Peng, Juan
    Probst, Danielle
    Zaleta, Alexandra
    Benson, Don
    Cohn, David E.
    Lustberg, Maryam
    Carson, William E.
    Magalang, Uly
    PSYCHO-ONCOLOGY, 2019, 28 (01) : 76 - 84
  • [44] Re: Response to In regard to Ding et al. 2020: "Managing Cancer and Living Meaningfully (CALM) Intervention on Chemotherapy Related Cognitive Impairment in Breast Cancer Survivors"
    Cheng, Huaidong
    Ding, Ke
    Yao, Senbang
    INTEGRATIVE CANCER THERAPIES, 2023, 22
  • [45] Effects of the CALM intervention on resilience in Chinese patients with early breast cancer: a randomized trial
    Shaochun Liu
    Runze Huang
    Anlong Li
    Sheng Yu
    Senbang Yao
    Jian Xu
    Lingxue Tang
    Wen Li
    Chen Gan
    Huaidong Cheng
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 18005 - 18021
  • [46] Effects of the CALM intervention on resilience in Chinese patients with early breast cancer: a randomized trial
    Liu, Shaochun
    Huang, Runze
    Li, Anlong
    Yu, Sheng
    Yao, Senbang
    Xu, Jian
    Tang, Lingxue
    Li, Wen
    Gan, Chen
    Cheng, Huaidong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (20) : 18005 - 18021
  • [47] Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: A randomized controlled trial
    Rummans, TA
    Clark, MM
    Sloan, JA
    Frost, MH
    Bostwick, JM
    Atherton, PJ
    Johnson, ME
    Gamble, G
    Richardson, J
    Brown, P
    Martensen, J
    Miller, J
    Piderman, K
    Huschka, M
    Girardi, J
    Hanson, J
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (04) : 635 - 642
  • [48] A Pilot Randomized, Controlled Trial of the Effectiveness of a Psychoeducational Intervention on Family Caregivers of Patients With Advanced Cancer
    Leow, Mabel
    Chan, Sally
    Chan, Moon Fai
    ONCOLOGY NURSING FORUM, 2015, 42 (02) : 143 - 143
  • [49] Effects of Managing Cancer and Living Meaningfully on Cancer-Related Fatigue and Cytokine Levels in Gastrointestinal Cancer Patients
    Cai, Yinlian
    Zhang, Qianqian
    Gan, Chen
    Xu, Jian
    Yu, Sheng
    Tang, Lingxue
    Yao, Senbang
    Li, Wen
    Huang, Runze
    Cheng, Huaidong
    INTEGRATIVE CANCER THERAPIES, 2023, 22
  • [50] A Randomized Controlled Trial of Betamethasone on Fatigue in Patients With Advanced Cancer
    Miyazaki, Kikuko
    Ikenaga, Masayuki
    Sato, Tosiya
    Ueshima, Kenji
    Nawata, Shuichi
    Horimatsu, Takahiro
    Komori, Eisaku
    Kirishima, Toshihiko
    Kawabata, Kunihiro
    Kawamura, Takashi
    Kasai, Hiroi
    Suzukamo, Yoshimi
    Matsuzaki, Keiichi
    Kuwabara, Yoshihiro
    Nakayama, Takeo
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2024, 67 (05) : 393 - 401.e1